Cancer drug shows promise for lewy body dementia?
NCT ID NCT04002674
First seen Apr 04, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study tested a cancer drug called nilotinib in 43 people with Dementia with Lewy Bodies (DLB), the second most common dementia in older adults. The goal was to see if the drug is safe and tolerable, and how it affects brain biomarkers. Participants received either nilotinib or a placebo for 6 months, with safety and brain scans monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.